Tamoxifen

ChemicalBook > CAS DataBase List > Tamoxifen

Antiestrogen drug Origin of the study Uses Pharmacokinetics Side effects Contraindications Precautions Drug interactions

Product Name: Tamoxifen
CAS No.: 10540-29-1
Chemical Name: Tamoxifen
Synonyms: TAMOXIFEN BASE;Novaldex;Mammaton;amoxifen;z-tamoxifen;Genox;C07108;Tamoxen;ici47699;TAMOXIFEN
CBNumber: CB9438781
Molecular Formula: C26H29NO
Formula Weight: 371.51
MOL File: 10540-29-1.mol

Less

Tamoxifen Property

Melting point:: 97-98 °C(lit.)
Boiling point:: 501.18°C (rough estimate)
Density: 1.0630 (rough estimate)
vapor pressure: 0Pa at 25℃
refractive index: 1.6000 (estimate)
storage temp.: 2-8°C
solubility: H2O: insoluble <0.1% at 20°C
pka: pKa 8.71(H2O t = 25 I = 0.025) (Uncertain)
color: Crystals from pet ether
Water Solubility: Insoluble in water. Soluble in methanol, ethanol, propanol or propylene glycol.Soluble in dimethyl sulfoxide, dichloromethane and ethanol. Insoluble in water.
Merck: 13,9137
Stability:: Light Sensitive
InChIKey: NKANXQFJJICGDU-QPLCGJKRSA-N
LogP: 6.3 at 20℃
CAS DataBase Reference: 10540-29-1(CAS DataBase Reference)
IARC: 1 (Vol. 66, 100A) 2012
EPA Substance Registry System: Tamoxifen (10540-29-1)

Less

Safety

Hazard Codes: T,Xi
Risk Statements: 45-60-61-64-36/37/38
Safety Statements: 53-45-36-26
WGK Germany: 3
RTECS: KR5919600
HS Code: 29221990
Hazardous Substances Data: 10540-29-1(Hazardous Substances Data)
Toxicity: LD50 orl-rat: 4100 mg/kg DRFUD4 9,186,84

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H350May cause cancer

H360May damage fertility or the unborn child

H410Very toxic to aquatic life with long lasting effects

Precautionary statements

P201Obtain special instructions before use.

P273Avoid release to the environment.

P308+P313IF exposed or concerned: Get medical advice/attention.

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: T2859
Product name: Tamoxifen
Purity: powder, Suitable for cell culture
Packaging: 0.5G
Price: $187
Updated: 2024/03/01

Sigma-Aldrich

Product number: T2859
Product name: Tamoxifen
Purity: powder, Suitable for cell culture
Packaging: 1G
Price: $310
Updated: 2024/03/01

Sigma-Aldrich

Product number: T-143
Product name: Tamoxifensolution
Purity: 1?mg/mLinmethanol,certifiedreferencematerial,ampuleof1?mL,Cerilliant?
Packaging: 1ML
Price: $112
Updated: 2024/03/01

Sigma-Aldrich

Product number: 85256
Product name: Tamoxifen
Purity: analytical standard
Packaging: 50mg
Price: $70.5
Updated: 2024/03/01

Sigma-Aldrich

Product number: 06734
Product name: Tamoxifen
Purity: certified reference material, TraceCERT
Packaging: 50mg
Price: $123
Updated: 2024/03/01

Less

Tamoxifen Chemical Properties,Usage,Production

Antiestrogen drug

Tamoxifen is non-steroidal anti-estrogen drugs. Its structure is similar to estrogen, existing Z type and O type isomers. The physical and chemical properties are different from each other, and physiological activity is different. E type has weak estrogenic activity, Z type having the effect of anti-estrogen. If the estrogen receptor (ER) is present in breast cancer cells, estrogen enters into tumor cells and binds with ER, promoting mRNA and DNA synthesis of tumor cells, stimulating tumor cell growth. However, Tamoxifen Z isomer enters into the cell, competitively binding with ER to form receptor complexes, inhibiting that estrogen plays an role, and inhibiting proliferation of breast cancer cells. Clinically it is mainly used for high levels of estrogen in breast cancer patients, which combines with androgen and other anticancer drugs (such as doxorubicin, etc., enhancing the effectiveness and showing good effect in postmenopausal patients with advanced breast cancer. Oral: once 10~20mg, 2 times 1 day. Common side effects are flushing, genital itching, occasional vaginal bleeding, a few may have a headache, fluid retention, for a long time may have retinal disease, vision loss, the other can have bone marrow suppression and gastrointestinal reactions.
Tamoxifen is used to treat breast cancer, and can reduce mortality and recurrence rate of estrogen-dependent breast cancer patients, so it has a good prospect. Another endocrine therapy aromatase inhibitor, it can inhibit effect of aromatase, preventing that the and rostenedione secreted by adrenal gland is transformed into estrogen in peripheral tissues (fat, skin, muscle), further reducing estrogen levels in postmenopausal women. It is currently one of the important means to treat postmenopausal patients with estrogen and progesterone receptor-positive breast cancer.

Figure 1 Mechanism of action of Tamoxifen and aromatase inhibitors

Origin of the study

In the 1960s, as for initial research of estrogen drug, scientists found that anti-estrogen drugs can prevent endometrial hyperplasia and embryo implantation in rats, and has the role of contraception, hoping that it can be used as contraceptives for use in humans. In1966 UK reproductive endocrinologist Walpole firstly reported study of Tamoxifen. When investigating an anti-estrogen substance-tristyrylphenol, they found that its two derivatives had different physiological effects. They used vaginal epithelium keratosis index and uterine weight growth index as the evaluation index. Results showed that homeopathic structure (ICI47,699) has estrogen-like effects on uterus and vaginal epithelial cells in rat and mice; trans structure (ICI46,747) has very weak estrogenic effect on vaginal epithelial cells in rat, has an anti-estrogenic effect on the uterus, which can terminate early pregnancy and inhibit ovulation, but it also has anti-estrogenic effect on uterus and vaginal epithelial cells in mouse. Trans structure ICI46,747 which is now Tamoxifen, scientists expect that ICI46,747 can be used as a new contraceptives in humans. However, during the clinical trial, they found that the drug did not show the same effect in rats, but the drug can stimulate endometrial hyperplasia, and promote ovulation. Thus, clinically Tamoxifen was firstly used as ovulation drugs in anovulatory infertility patients, and still in use. For the current field of assisted reproductive technology treatment of ovarian hyperstimulation program, it also has a good effect on ovulation. Thus, Tamoxifen had both estrogen-like and anti-estrogenic effects, and showed different effects on different species and tissues.

Figure 2 The structural formula of Tamoxifen.
The above information is edited by the Chemicalbook of Liu Yujie.

Uses

1. Treatment for Women with metastatic breast cancer recurrence.
2. Used as adjuvant therapy after surgery for breast cancer metastasis, and relapse prevention.
3. For the treatment of ovarian cancer, endometrial cancer and endometriosis.

Pharmacokinetics

This product is easily absorbed orally, generally three hours after taking the drug concentration in the blood is up to the peak; because of enterohepatic circulation, the concentration of product is a more lasting in vivo; in the liver metabolism this product mainly excreted in the feces by biliary (58% to 100% ) rarely excreted in urine (only 2% to 21%); after the anima taking isotopically labeled this product, it is found that radioactivity is the highest in animal ovaries.After it is used for post-menopausal women, the concentration in endometrium is 2 times in plasma .

Side effects

1. Early treatment of bone cancer pain and may be a transient increase, continued treatment can be gradually reduced.
2. gastrointestinal reactions: loss of appetite, nausea, vomiting, diarrhea.
3. Reproductive system: menstrual disorders, amenorrhea, vaginal bleeding, genital itching, endometrial hyperplasia, endometrial polyps and endometrial cancer.
4. Skin: facial flushing, rash, hair loss.
5. Bone marrow: occasionally neutropenia and thrombocytopenia.
6. Liver function: occasionally abnormalities.
7. Eyes: using for long time (17 months or more) and large number (240~320mg per day), may appear retinal lesions or corneal opacity .
8. The rare and needed attention of side effects: insanity, pulmonary embolism (showing shortness of breath), thrombosis, weakness, drowsiness.

Contraindications

1. It is contraindicated in patients who are allergic to this product.
2. It is contraindicated in patients with fundus diseases.
3. It is contraindicated in patients who have history of deep vein thrombosis and pulmonary embolism or are receiving anticoagulant therapy.
4. It is contraindicated in pregnant woman and nursing mothers.

Precautions

1. Abnormal liver function should be used with caution. If bone metastasis, patients are needed to regularly check blood calcium in the early treatment.
2.Pregnancy safety of this drug is classified as D class by FDA.

Drug interactions

1. The drug combines with fluorouracil, cyclophosphamide, methotrexate, vincristine and doxorubicin, etc. and can improve the effects.
2. The drug can increase the dopaminergic effect of bromocriptine mesylate.
3. The data show that the drug can prolong neuromuscular blockade of atracurium.
4. The drug can enhance the effect of anticoagulants, not combining with anticoagulants (such as warfarin, two coumarin anticoagulants).
5. Antacids and cimetidine, famotidine, ranitidine can change the pH of the stomach, making the drug enteric-coated tablets decomposed and showing a stimulating effect on the stomach, so when l in combination , these drugs should be interval of 1 to 2 hours.
6. Estrogen can affect the therapeutic effect of the drug, should not be combined.
7. The in vitro test results show that the drug may inhibit the metabolism of tacrolimus.
8.When in combination with mitomycin, the risk of hemolytic syndrome and hematuria increased.
9. The drug combines with triptolide which can lead to accelerate tumor growth in mice, so the combination should be cautious.
10. with allopurinol, the drug may increase liver toxicity.
11. The drug combines with other cytotoxic drugs, increasing the risk of thromboembolism.

Description

In 1966, ICI Pharmaceuticals (now AstraZeneca) first synthesized tamoxifen in the hope of developing a morning-after contraceptive pill. The UK patent for this compound was in place in 1962, whereas the US patent was repeatedly denied until the 1980s. Tamoxifen was approved for a fertility treatment but it was not proven as useful in regulating human contraception. Even though there was a link between estrogen and breast cancer, developing a cancer treatment was not a priority at the time. In 1971, the first clinical study showed a convincing effect of tamoxifen in treating advanced breast cancer. From 1971 to 1977, this drug was neither clinically nor financially remarkable. In 1980s, however, publications first showed that tamoxifen, in addition to chemotherapy, improved survival for patients with early stage breast cancer. In 1998, the meta-analysis by the Oxford-based Early Breast Cancer Trialists’ Collaborative Group showed that tamoxifen did indeed save lives in early breast cancer. In 2001, tamoxifen sales were over $1.024 billion. Since the expiration of the patent in 2002, it is now widely available as a generic drug. By 2004, tamoxifen was the best selling hormonal drug for the treatment of breast cancer.

Chemical Properties

White Crystalline Solid

Originator

Nolvadex,I.C.I.,UK,1973

Uses

A nonsteroidal estrogen antagonist of interest in the treatment of some forms of breast cancer. Tamoxifen is a Protein Kinase C inhibitor, and induces apoptosis in human malignant glioma cell lines

Uses

Tamoxifen is a selective estrogen response modifier (SERM), protein kinase C inhibitor and anti-angiogenetic factor. Tamoxifen is a prodrug that is metabolized to active metabolites 4-hydroxytamoxifen (4-OHT) and endoxifen by cytochrome P450 isoforms CYP2D6 and CYP3A4. In breast cancer, the gene repressor activity of tamoxifen against ERBB2 is dependent upon PAX2. Blocks estradiol-stimulated VEGF production in breast tumor cells. Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response mo difiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

Uses

Tamoxifen has been used to facilitate the recombination of ect2^flox allele in mouse organs⁹¹. It has also been used to study its effect on lipopolysaccharide (LPS)-induced microglial activation⁹².

Indications

Tamoxifen (Nolvadex) is a synthetic antiestrogen used in the treatment of breast cancer. Normally, estrogens act by binding to a cytoplasmic protein receptor, and the resulting hormone–receptor complex is then translocated into the nucleus, where it induces the synthesis of ribosomal RNA (rRNA) and messenger RNA (mRNA) at specific sites on the DNA of the target cell. Tamoxifen also avidly binds to estrogen receptors and competes with endogenous estrogens for these critical sites. The drug–receptor complex has little or no estrogen agonist activity.Tamoxifen directly inhibits growth of human breast cancer cells that contain estrogen receptors but has little effect on cells without such receptors.

Indications

Tamoxifen is a partial estrogen agonist in breast and thus is used as a treatment and chemopreventative for breast cancer. Tamoxifen is a full agonist in bone and endometrium, and prolonged use of tamoxifen leads to a fourfold to fivefold increase in the incidence of endometrial cancer. See Chapter 56 for a detailed discussion of the use of tamoxifen in breast cancer.

Definition

ChEBI: Tamoxifen is a tertiary amino compound and a stilbenoid. It has a role as an estrogen receptor antagonist, a bone density conservation agent, an estrogen receptor modulator, an estrogen antagonist, an angiogenesis inhibitor, an EC 2.7.11.13 (protein kinase C) inhibitor, an EC 1.2.3.1 (aldehyde oxidase) inhibitor and an antineoplastic agent. It derives from a hydride of a stilbene.

Manufacturing Process

To the Grignard reagent prepared from 0.59 part of magnesium, 3.95 parts of bromobenzene and 50 parts of ether there are added 7.5 parts of 4-(β- dimethylaminoethoxy)-α-ethyldesoxybenzoin in 50 parts of ether. After heating under reflux for 3 hours, the mixture is decomposed by the addition of a solution of 60 parts of ammonium chloride in 150 parts of water. The mixture is separated, and the ethereal layer is dried with anhydrous sodium sulfate, and the ether is evaporated. The residue is crystallized from methanol. There is thus obtained 1-(p-β-dimethylaminoethoxyphenyl)-1,2- diphenylbutan-1-ol, melting point 120°C to 121°C.
2.15 parts of 1-(p-β-dimethylaminoethoxyphenyl)-1,2-diphenylbutan-1-ol, 25 parts of ethanol and 0.8 part of 10 N hydrochloric acid are heated together under reflux for 3 hours. The solution is evaporated to dryness under reduced pressure and the residue is extracted with methylene chloride. The methylene chloride extract is decolorized with charcoal and then evaporated to dryness. The residue is dissolved in 100 parts of water, the solution is basified by the addition of sodium hydroxide solution, and the precipitated solid is extracted three times, each time with 50 parts of ether. The combined extracts are dried with anhydrous sodium sulfate and then evaporated. The residue is crystallized from aqueous methanol, and there is thus obtained 1-(p-β- dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene, melting point 95°C to 96°C.

brand name

Nolvadex (AstraZeneca); Soltamox (Savient).

Therapeutic Function

Antiestrogen, Antineoplastic

World Health Organization (WHO)

Tamoxifen is an anti-estrogen agent used mainly to treat breast cancer. Tamoxifen is listed in the WHO Model List of Essential Drugs.

General Description

Biochem/physiol Actions

Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

Mechanism of action

Tamoxifen is slowly absorbed, and maximum serum levels are achieved 4 to 7 hours after oral administration. The drug is concentrated in estrogen target tissues, such as the ovaries, uterus, vaginal epithelium, and breasts. Hydroxylation and glucuronidation of the aromatic rings are the major pathways of metabolism; excretion occurs primarily in the feces.

Pharmacokinetics

Circulating levels of the demethylated metabolite at steady state are up to twice the level of the parent drug, because the elimination half-life of N-demethyl tamoxifen is 14 days, compared with 7 days for tamoxifen. Tamoxifen demonstrates only weak estrogenic effects at several sites, including the endometrium and bone, and on the lipid profile. Tamoxifen undergoes rapid N-dem ethylation to its major metabolite, N-dem ethyltamoxifen, by CYP3A4 and via CYP2D6 to its minor metabolite, 4-hydroxytam oxifen. Evidence suggests that 4-hydroxytamoxifen is the active metabolite of tamoxifen, with a higher binding affinity than the parent drug for the ER

Clinical Use

Tamoxifen is a SERM that is used as an antiestrogen in the treatment of estrogen-dependent breas Tcancer following prim ary treatment (c hemotherapy and/or surgery).

Side effects

Tamoxifen administration is associated with few toxic side effects, most frequently hot flashes (in 10–20% of patients) and occasionally vaginal dryness or discharge. Mild nausea, exacerbation of bone pain, and hypercalcemia may occur.

Safety Profile

Confirmed human carcinogen. Moderately toxic by ingestion and intraperitoneal routes. Human systemic effects by an unspecified route: nausea or vomiting, leukopenia, thrombocytopenia, and skin changes. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

Synthesis

Tamoxifen, (Z)-2-[p-(1,2-diphenyl-1-butenyl)phenoxy]N,N-dimethylethylamine (28.2.8), is synthesized from |á-ethyldezoxybenzoin. Interaction of this with 4- methoxyphenylmagnesium bromide gives the corresponding carbinol (28.2.5). Its dehydration in acidic conditions gives a derivative of stilbene (28.2.6), and further heating of which with quinidine hydrochloride as a demethylating agent gives 2-[p-(1,2-diphenyl- 1-butenyl)phenol] (28.2.7). The phenolic hydroxyl is further alkylated by dimethylaminoethylchoride using sodium ethoxide as a base, which forms a mixture of E and Z isomers of the final product. The desired Z isomer, tamoxifen (28.2.8) is isolated by fractional crystallization from petroleum ester.

in vitro

ic50s for growth inhibition ranged from 5.5–10 μm, and were not affected by estrogen. tamoxifen-mediated growth inhibition was not associated with induction of tgf-β. however, tamoxifen treatment was associated with inhibition of pkc, which was followed by induction of p21waf1/cip1, rb dephosphorylation, and g1/s phase cell cycle arrest [1].

in vivo

the tumor cell kinetics of mcf-7 human breast carcinoma xenografts grown in nude mice can be significantly altered by hormonal manipu lation. tamoxifen treatment or e2 deprivation resulted in an approximate doubling of the tpol and an approximately 40% reduction in labeling index as compared to e2-stimulated tumors. an increase in cell loss rate was calculated for both tamoxifen treatment and e2 deprivation [2].

Drug interactions

Potentially hazardous interactions with other drugs
Anticoagulants: effects of coumarins enhanced.
Antidepressants: metabolism of tamoxifen to active metabolite possibly inhibited by fluoxetine and paroxetine - avoid.
Antipsychotics: increased risk of ventricular arrhythmias with droperidol - avoid.
Buproprion: metabolism of tamoxifen to active metabolite possibly inhibited - avoid.
Cinacalcet: metabolism of tamoxifen to active metabolite possibly inhibited - avoid.

IC 50

5.5–10 μm

Carcinogenicity

Tamoxifen is known to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in humans.

Metabolism

Tamoxifen is extensively metabolised by cytochrome P450 isoenzymes, to active metabolites that include N-desmethyltamoxifen, 4-hydroxytamoxifen, and 4-hydroxy-N-desmethyltamoxifen (endoxifen).
Metabolism is by hydroxylation, demethylation and conjugation.
In-vitro studies suggest that both N-desmethyltamoxifen and 4-hydroxytamoxifen are further metabolised to endoxifen.
Elimination occurs, chiefly as conjugates with practically no unchanged drug, principally through the faeces and to a lesser extent through the kidneys.

storage

Room temperature

References

[1] rohlff c, blagosklonny mv, kyle e, kesari a, kim iy, zelner dj, hakim f, trepel j, bergan rc. prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase c and induction of p21(waf1/cip1). prostate. 1998 sep 15;37(1):51-9.
[2] jann n. sarkaria, david f. c. gibson, v. craig jordan, john f. fowler, mary j. lindstrom, andr. timothy mulcahy. tamoxifen-induced increase in the potential doubling time of mcf-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. cancer research 5.1. 4413-1417, september 15, 1993.
[3] osborne ck. tamoxifen in the treatment of breast cancer. n engl j med. 1998 nov 26;339(22):1609-18.

Tamoxifen Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Tamoxifen Suppliers

Canada 3 China 281 France 1 India 4 Switzerland 1 United Kingdom 7 United States 19 Global 316

Hubei Zhaoke BIO-CHEMICAL Co., Ltd.

Tel: 027-87607080 13433334465
Email: 396587392@qq.com
Country: China
ProdList: 347
Advantage: 58

Hubei Aiputi Bioengineering Co., Ltd.

Tel: 17762444226
Email: d17762444226@163.com
Country: China
ProdList: 2402
Advantage: 58

TargetMol Chemicals Inc.

Tel: 021-33632979 15002134094
Fax: 021-33632979
Email: marketing@targetmol.com
Country: China
ProdList: 7934
Advantage: 58

Suzhou Unite pharmTech Co., Ltd ,

Tel: 792-3901125 13222993784
Fax: 0512-62575043
Email: sales@unite-pharm.com
Country: China
ProdList: 160
Advantage: 56

Hubei Awin Bio-Chemical Co., Ltd

Tel: 17362549610
Email: 312523773@qq.com
Country: China
ProdList: 115
Advantage: 58

Chembest Research Laboratories Limited

Tel: 021-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6011
Advantage: 61

Energy Chemical

Tel: 021-021-58432009 400-005-6266
Fax: 021-58436166
Email: sales8178@energy-chemical.com
Country: China
ProdList: 44751
Advantage: 61

Adamas Reagent, Ltd.

Tel: 400-6009262 16621234537
Fax: 021-64823266
Email: zhangsn@titansci.com
Country: China
ProdList: 14113
Advantage: 59

Chemsky（shanghai）International Co.,Ltd.

Tel: 021-50135380
Email: shchemsky@sina.com
Country: China
ProdList: 32344
Advantage: 50

Jinan Trio PharmaTech Co., Ltd.

Tel: +86 (531) 88811783
Fax: +86 (531) 55696010 QQ 1762738062
Email: sales@trio-pharmatech.com (International market)
Country: China
ProdList: 1856
Advantage: 62

Daicel Chiral Technologies (China)CO.,LTD

Tel: 021-50460086-9 15921403865
Fax: +86-21-50462321
Email: han_yajun@dctc.daicel.com
Country: China
ProdList: 6818
Advantage: 65

Syntechem Co.,Ltd

Tel
Fax: E-Mail Inquiry
Email: info@syntechem.com
Country: China
ProdList: 12990
Advantage: 57

BEST-REAGENT

Tel: 400-1166-196 18981987031
Fax: 028-84555506 800101999
Email: cdhxsj@163.com
Country: China
ProdList: 11726
Advantage: 57

Tianjin heowns Biochemical Technology Co., Ltd.

Tel: 400 638 7771
Email: sales@heowns.com
Country: China
ProdList: 14443
Advantage: 57

Sinopharm Chemical Reagent Co,Ltd.

Tel: 86-21-63210123
Fax: 86-21-63290778 86-21-63218885
Email: sj_scrc@sinopharm.com
Country: China
ProdList: 9823
Advantage: 79

Spectrum Chemical Manufacturing Corp.

Tel: 021-021-021-67601398-809-809-809 15221380277
Fax: 021-57711696
Email: marketing_china@spectrumchemical.com
Country: China
ProdList: 9664
Advantage: 60

ShangHai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847 13636370518
Fax: 021-55068248
Email: shyysw007@163.com
Country: China
ProdList: 4941
Advantage: 60

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12338
Advantage: 58

NCE Biomedical Co.,Ltd.

Tel: 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax: +86-27-87599188
Country: China
ProdList: 1494
Advantage: 55

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7553
Advantage: 61

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 400-6206333 18521732826;
Fax: 021-50323701
Email: market@aladdin-e.com
Country: China
ProdList: 25015
Advantage: 65

The future of Shanghai Industrial Co., Ltd.

Tel: 021-61552785
Fax: 021-55660885
Email: sales@shshiji.com
Country: China
ProdList: 9552
Advantage: 55

China Nobel Chem Co., Limited

Tel: +86(0)21 60484900
Fax: +86(0)21 60484900
Country: China
ProdList: 764
Advantage: 50

Hubei Datong Bio-Chemical Technology Co.,Ltd

Tel: 027-87666700
Fax: 027-87666700 skype-lydia0189
Email: xuri@hbdatongchem.com
Country: China
ProdList: 147
Advantage: 55

Guangzhou Isun Pharmaceutical Co., Ltd

Tel: 020-39119399 18927568969
Fax: 020-39119999
Email: isunpharm@qq.com
Country: China
ProdList: 4428
Advantage: 55

Hubei XinyuanShun Chemical Co., Ltd.

Tel: 13971561712, 13995564702, 027-50664929
Fax: 027-50664927
Email: hbeixys2001@163.com
Country: China
ProdList: 3123
Advantage: 55

Huainan Kedi Chemical Factory

Tel: 0554-2106669
Fax: 0554-2666215
Email: sales1@kedichem.com
Country: China
ProdList: 4928
Advantage: 55

ChemStrong Scientific Co.,Ltd

Tel: 0755-0755-66853366 13670046396
Fax: 0755-28363542
Email: sales@chem-strong.com
Country: China
ProdList: 17982
Advantage: 56

Chengdu HuaXia Chemical Reagent Co. Ltd

Tel: 400-1166-196 13458535857
Fax: QQ：800101999
Email: cdhxsj@163.com
Country: China
ProdList: 13358
Advantage: 58

Wuhan Dahua Pharmaceutical Co., Ltd.

Tel: 027-59262863 13277907145 3091977954
Fax: 027-59420980
Country: China
ProdList: 4951
Advantage: 58

Shanghai YuLue Chemical Co., Ltd.

Tel: 021-60345187 13671753212
Fax: 021-34702061
Email: lzz841106@aliyun.com
Country: China
ProdList: 10287
Advantage: 55

LETOPHARM LIMITED

Tel: +86-21-5821 5861
Fax: +86-21-5106 2861
Email: sales@letopharm.com
Country: China
ProdList: 2384
Advantage: 58

Chizhou Kailong Import and Export Trade Co., Ltd.

Tel
Fax: -
Email: xg01_gj@163.com
Country: China
ProdList: 9503
Advantage: 50

Sigma-Aldrich

Tel: 021-61415566 800-8193336
Email: orderCN@merckgroup.com
Country: China
ProdList: 51471
Advantage: 80

Wuhan Biocar Bio-Pharm Co., Ltd.

Tel: 86 15387057351
Fax: 86 027 87050469
Email: sales@biocar.cn
Country: China
ProdList: 114
Advantage: 55

Struchem Co., Ltd.

Tel: 0512-0512-63009836 15365350169
Fax: 0512-63006936
Email: helen@struchem.com
Country: China
ProdList: 3989
Advantage: 60

Shanghai Synchem Pharma Co., ltd

Tel: 021-61984905-1 18016477331
Email: synchempharma@aliyun.com
Country: China
ProdList: 6454
Advantage: 55

SPIRO PHARMA

Tel
Fax: -
Email: eric_feng1954@126.com
Country: China
ProdList: 9254
Advantage: 55

Shanghai Send Pharmaceutical Technology Co., Ltd.

Tel: 021-50266790 Q3382968513
Fax: QQ3382968513
Email: Hailey@shsendpharm.com
Country: China
ProdList: 3170
Advantage: 55

AOKBIO Inc.

Tel: 021-68712331 3286104197
Fax: 021 68712331
Country: China
ProdList: 323
Advantage: 55

ShangHai Siyan Biological Technology Co., Ltd.

Tel: 021-50908862，442785678，326799392 18721037013
Fax: 021-50908862
Email: siyansales@126.com
Country: China
ProdList: 9638
Advantage: 58

Henan CoreyChem Co., Ltd

Tel: 0371-86658258
Fax: 0371-60996044
Email: info@coreychem.com
Country: China
ProdList: 10457
Advantage: 58

Guangzhou QiYun Biotechnology Co., Ltd.

Tel: 020-61288194 61288195
Fax: 020-61288700
Email: 505721671@qq.com
Country: China
ProdList: 3868
Advantage: 58

parabiochem

Tel: 025-83453382-8005
Fax: 025-83453382
Email: sale@parabiochem.com
Country: China
ProdList: 9604
Advantage: 55

Lancrix Chemicals

Tel: 86-21-50817262
Fax: 86-21-57712035
Email: sales@lancrix.com
Country: China
ProdList: 1503
Advantage: 55

Chengdu Dianchun Technology Co., Ltd

Tel: 400-1166-196 18502815961
Fax: QQ：800101999
Email: cdhxsj@163.com
Country: China
ProdList: 14623
Advantage: 60

Grader reagent

Tel: 18221735425
Email: sales@xinpingchem.com
Country: China
ProdList: 9951
Advantage: 58

Beijing Solarbio Science & Tecnology Co., Ltd.

Tel: 010-50973130 4009686088
Email: 3193328036@qq.com
Country: China
ProdList: 29797
Advantage: 68

Shenzhen Simeiquan Biotechnology Co. Ltd

Tel: 18126413629 0755-23311925 2355327053
Fax: 0755-23311925
Email: abel@ycgmp.com
Country: China
ProdList: 5115
Advantage: 58

Shanghai Champ Biopharmaceuticals Co., Ltd.

Tel: 021-61537865 13585780846
Email: sales@champchem.com
Country: China
ProdList: 349
Advantage: 58

Less

View Lastest Price from Tamoxifen manufacturers

Wuhan Cell Pharmaceutical Co., Ltd

Product: Tamoxifen 10540-29-1
Price: US $3.00-865.00/g
Min. Order: 1g
Purity: 99.99%
Supply Ability: 1000kg
Release date: 2023-10-09

Shanghai Longyu Biotechnology Co., Ltd.

Product: Tamoxifen Citrate 10540-29-1
Price: US $1.00/g
Min. Order: 1g
Purity: 99%
Supply Ability: 20tons
Release date: 2021-11-29

Hong Kong Excellence Biotechnology Co., Ltd.

Product: Tamoxifen 10540-29-1
Price: US $100.00/kg
Min. Order: 1kg
Purity: 99.9%
Supply Ability: 20tons
Release date: 2023-10-12

10540-29-1, TamoxifenRelated Search:

Chlorodiphenylphosphine Diphenyldimethoxysilane Dimethyldimethoxysilane Diphenylsilane tert-Butylchlorodiphenylsilane phenoxybenzamine Diphenylphosphine Diphenyldiethoxysilane trans,trans-2,4-Undecadienal Biphenyl 1,5-Diphenylcarbazide TAMOXIFEN CITRATE(RG) TAMOXIFEN CITRATE,TAMOXIFEN CITRATE SALT Toremifene Nafoxidine IDOXIFENE TAMOXIFEN, 3-HYDROXY-, CITRATE, (E)- TAMOXIFEN, 4-HYDROXY-

(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine

2-[4-[(Z)-1,2-Di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine

Mammaton

2-[4-[(Z)-1,2-Diphenyl-1-butenyl]phenoxy]-N,N-dimethylethanamine

2-[p-[(Z)-1,2-Diphenyl-1-butenyl]phenyloxy]-N,N-dimethylethanamine

N,N-Dimethyl-2-[p-[(Z)-1,2-diphenyl-1-butenyl]phenoxy]ethanamine

C07108

Tamoxifen,(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine

1-p-β-DiMethylaMinoethoxyphenyl-trans-1,2-diphenylbut-1-ene

Novaldex

(Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-diMethylethanaMine

TaMoxiefen

EthanaMine,2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-diMethyl-

(z)-2-(4-(1,2-diphenyl-1-butenyl)phenoxy)phenoxy)-n,n-dimethylethanamine

(z)-2-(para-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylamine

1-para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene

1-p-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene

Tamoxifen, >=99%

Tamoxifen(ICI46,474)

(Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene

TAMOXIFEN

TAMOXIFEN BASE

TRANS-2-[4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY]-N,N-DIMETHYLETHYLAMINE

(Z)-2-[4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY]-N,N-DIMETHYLETHANAMINE

[Z]-1-[P-DIMETHYLAMINOETHOXYPHENYL]-1,2-DIPHENYL-1-BUTENE

Genox

Tamoxen

tamoxifen free base

Ethanamine, 2-4-(1Z)-1,2-diphenyl-1-butenylphenoxy-N,N-dimethyl-

(Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine

ici47699

n-dimethyl-2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-(z)-ethylamin

Nolvadex-D

tamoxifen(z)

tamoxifendrugstandardsolution

trans-tamoxifen

z-tamoxifen

TAMOXIFEN (ICI 47699)

2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine

Tamoxiphen CAS NO.10540-29-1

Tamoxifen citrate for performance test CRS

Tamoxifen citrate CRS

Steroids Raw Powder Tamoxife

amoxifen

Tamoxifen USP/EP/BP

Tamoxifen (1.0 mg/mL in Methanol)

Tamoxifen Nolvadex

10540-29-1

C26H28NO

C6H5CC2H5CC6H5C6H4OCH2CH2NCH32

C25H27NOHCl

C26H29NO

C2514CH29NO

Antibiotics A to Z

Antibiotics

BioChemical

Antibiotics T-Z

Aromatics